clinical trial · NCT06961968
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophreniailoperidoneplacebo
brief summary
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
started
May 14, 2025
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Jan 12, 2026
official title
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol